On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.

Raising breast cancer awareness beyond borders
The Gynecological Surgery Department at Paris Saint-Joseph Hospital was pleased to take part in a Franco-Serbian friendship evening dedicated to Pink October and the fight

